N/A
Manufactured by Mayne Pharma
11,158 FDA adverse event reports analyzed
Last updated: 2026-04-15
TAMOXIFEN CITRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Mayne Pharma. The most commonly reported adverse reactions for TAMOXIFEN CITRATE include FATIGUE, NAUSEA, DIARRHOEA, ARTHRALGIA, MALIGNANT NEOPLASM PROGRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TAMOXIFEN CITRATE.
Out of 5,615 classified reports for TAMOXIFEN CITRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,158 FDA FAERS reports that mention TAMOXIFEN CITRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, NAUSEA, DIARRHOEA, ARTHRALGIA, MALIGNANT NEOPLASM PROGRESSION, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Mayne Pharma in connection with TAMOXIFEN CITRATE. Always verify the specific product and NDC with your pharmacist.